Develops nanoparticle drug delivery systems for oncology therapies, focusing on improving drug efficacy and safety.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company based in Austin, Texas, dedicated to advancing therapies for cancer and other challenging diseases. The company focuses on developing, manufacturing, and commercializing innovative treatments that address critical unmet needs in oncology. Its primary focus lies in Rhenium-186 NanoLiposome, a patented radiotherapy designed to target central nervous system cancers such as recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
In pursuit of its mission, Plus Therapeutics, Inc. has entered into strategic partnerships such as a license agreement with NanoTx, Corp., aimed at further developing and commercializing novel treatments for glioblastoma. This collaboration underscores the company's commitment to leveraging cutting-edge technologies and partnerships to advance cancer therapies and improve patient outcomes. Originally known as Cytori Therapeutics, Inc., Plus Therapeutics rebranded in July 2019 to reflect its expanded focus and commitment to therapeutic innovation.
Founded in 1996, Plus Therapeutics has built a foundation of scientific expertise and strategic vision to drive forward its pipeline of promising treatments. With its headquarters in Austin, the company continues to inovate in the field of oncology, aiming to bring transformative therapies to patients in neeed worldwide.